Kamile Arıkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kamile Arıkan has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Ateş Kara
Division of Pediatric Infectious Diseases, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Türkiye
4 shared publications Mehmet Ceyhan
Hacettepe University Faculty of Medicine, Department of Infectious Diseases, Ankara, Turkey
4 shared publicationsAtes Kara
Hacettepe University Faculty of Medicine, Department of Infectious Diseases, Ankara, Turkey
3 shared publications- Elif Böncüoğlu
Department of Pediatric Infectious Diseases, Buca Seyfi Demirsoy Education and Research Hospital, Izmir Democracy University
3 shared publications - Elif Kıymet
Department of Pediatric Infectious Diseases, İzmir Bakırçay University Çiğli Training and Research Hospital, İzmir, Türkiye
3 shared publications Ali Bülent Cengiz
Hacettepe University Faculty of Medicine, Department of Infectious Diseases, Ankara, Turkey
2 shared publications
Latest Publications
- 19 February 2024
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 18 (Suppl 1) , 1-30
Çocukluk Çağı Ateş Yönetimi Değerlendirmesi
- 19 February 2024
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 18 (Suppl 1) , 1-30
Çocukluk Çağı Ateş Yönetimi Değerlendirmesi
- 19 February 2024
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 18 (Suppl 1) , 1-31
Evaluation of Childhood Fever Management
- 19 February 2024
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 18 (Suppl 1) , 1-31
Evaluation of Childhood Fever Management
- Open Access
- 31 December 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (4) , 549-555
Risk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study
Objectives: This study aimed to evaluate the risk of tuberculosis (TB) disease in children receiving biological agents for rheumatologic diseases, focusing on appropriate screening tests in a high-priority country for TB control. Patients and methods: One hundred nine children (56 females, 53 males; range, 3.4 to 16.2 years) who received any biological agent for rheumatologic diseases for more than two years between May 2012 and October 2021 were included in this retrospective study. Patients were screened for TB infection using tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Following the initial evaluation, patients were clinically examined for TB every three months by a comprehensive medical history and physical examination, and every 12 months using TST or IGRA. Results: At the initiation of the biological agent, the patients’ mean age was 12.4±4.5 years. The average follow-up duration was 3.6±1.3 years (range, 2.6 to 10.2 years) for patients treated with biological agents. Each patient had a documented Bacillus Calmette-Guérin vaccination. Before the initiating of therapy, TST was performed alone in 45 (41.3%) patients and in combination with IGRA in 64 (58.7%) patients. In the 64 patients who underwent both TST and IGRA, IGRA revealed nine (14.1%) positive results. Six (66.7%) of these nine patients, however, had negative baseline TST. Four (7.3%) of the 55 individuals whose initial IGRA results were negative also had positive TST results. Overall, no TB disease was observed after a follow-up period. Conclusion: This study reveals that biological agents were not associated with an increased risk of TB disease in closely monitored children. Additionally, the concomitant use of TST and IGRA for screening of TB is reasonable in patients receiving biological agents.
- 31 December 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (4) , 549-555
Open AccessRisk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study
Objectives: This study aimed to evaluate the risk of tuberculosis (TB) disease in children receiving biological agents for rheumatologic diseases, focusing on appropriate screening tests in a high-priority country for TB control. Patients and methods: One hundred nine children (56 females, 53 males; range, 3.4 to 16.2 years) who received any biological agent for rheumatologic diseases for more than two years between May 2012 and October 2021 were included in this retrospective study. Patients were screened for TB infection using tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Following the initial evaluation, patients were clinically examined for TB every three months by a comprehensive medical history and physical examination, and every 12 months using TST or IGRA. Results: At the initiation of the biological agent, the patients’ mean age was 12.4±4.5 years. The average follow-up duration was 3.6±1.3 years (range, 2.6 to 10.2 years) for patients treated with biological agents. Each patient had a documented Bacillus Calmette-Guérin vaccination. Before the initiating of therapy, TST was performed alone in 45 (41.3%) patients and in combination with IGRA in 64 (58.7%) patients. In the 64 patients who underwent both TST and IGRA, IGRA revealed nine (14.1%) positive results. Six (66.7%) of these nine patients, however, had negative baseline TST. Four (7.3%) of the 55 individuals whose initial IGRA results were negative also had positive TST results. Overall, no TB disease was observed after a follow-up period. Conclusion: This study reveals that biological agents were not associated with an increased risk of TB disease in closely monitored children. Additionally, the concomitant use of TST and IGRA for screening of TB is reasonable in patients receiving biological agents.
- 9 September 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (3) , 182-187
Çocuk Acil Servisine Kuduz Riskli Temas Sonrası Başvuran Hastaların Epidemiyolojik ve Klinik Özellikleri
- 9 September 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (3) , 182-187
Çocuk Acil Servisine Kuduz Riskli Temas Sonrası Başvuran Hastaların Epidemiyolojik ve Klinik Özellikleri
- 9 September 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (3) , 187-192
Epidemiological and Clinical Characteristics of Patients Admitted to the Pediatric Emergency Department After Exposure to the Risk of Rabies
- 9 September 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (3) , 187-192
Epidemiological and Clinical Characteristics of Patients Admitted to the Pediatric Emergency Department After Exposure to the Risk of Rabies
- 30 March 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (1) , 14-19
Change of Laboratory Findings of Acute Epstein-Barr Virus Infection According to Age Groups
- 30 March 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (1) , 14-19
Change of Laboratory Findings of Acute Epstein-Barr Virus Infection According to Age Groups
- 30 March 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (1) , 14-19
Change of Laboratory Findings of Acute Epstein-Barr Virus Infection According to Age Groups
- 30 March 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (1) , 14-19
Change of Laboratory Findings of Acute Epstein-Barr Virus Infection According to Age Groups
- 13 December 2022
- Published by Galenos Yayinevi in The Journal of Pediatric Research
- Vol. 9 (4) , 361-367
Micafungin Effectiveness in Treating Pediatric Patients with Proven Candidemia
- 13 December 2022
- Published by Galenos Yayinevi in The Journal of Pediatric Research
- Vol. 9 (4) , 361-367
Micafungin Effectiveness in Treating Pediatric Patients with Proven Candidemia
- 3 November 2021
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 89 (1) , 80-82
Breast Milk Protein Percentiles According to Gestational and Postnatal Age: Could It Be Used as a New Alternative in Guided Fortification?
Human milk is the first choice for infant nutrition but it must be multinutrient fortified for optimum growth and neurodevelopment in preterm infants. However, there is no consensus on ideal fortification method. The authors aimed to generate the human-milk protein content percentiles during the first five postnatal weeks in four preterm groups (n = 108) with median gestational age of 32 (23–36) wk, who were fed adjustably fortified breast milk in the NICU between October 2011 and June 2013. Total 540 breast milk samples of mothers of 108 infants were weekly analyzed for protein intake. It was observed that the median human-milk protein levels decreased throughout the five postnatal weeks in all groups. None of the preterm infants was able to take the recommended daily protein intake with the fortification protocol of the authors' unit. Preterm human-milk protein charts can be used as a new practical individualized fortification guiding method instead of laborious targeted or adjustable approaches currently in use.
- 3 November 2021
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 89 (1) , 80-82
Breast Milk Protein Percentiles According to Gestational and Postnatal Age: Could It Be Used as a New Alternative in Guided Fortification?
Human milk is the first choice for infant nutrition but it must be multinutrient fortified for optimum growth and neurodevelopment in preterm infants. However, there is no consensus on ideal fortification method. The authors aimed to generate the human-milk protein content percentiles during the first five postnatal weeks in four preterm groups (n = 108) with median gestational age of 32 (23–36) wk, who were fed adjustably fortified breast milk in the NICU between October 2011 and June 2013. Total 540 breast milk samples of mothers of 108 infants were weekly analyzed for protein intake. It was observed that the median human-milk protein levels decreased throughout the five postnatal weeks in all groups. None of the preterm infants was able to take the recommended daily protein intake with the fortification protocol of the authors' unit. Preterm human-milk protein charts can be used as a new practical individualized fortification guiding method instead of laborious targeted or adjustable approaches currently in use.